Capitainer develops intelligent solutions for self-sampling of blood and plasma, positioning itself in the self-sampling diagnostics market. The company’s product portfolio is described as disruptive and supported by solid data. Capitainer plans to scale up production capacity, enhance sales and marketing, and launch new products as part of its expansion. Management specifically cites efforts to grow in the EU and US markets. The company has secured a significant investment to support these initiatives and growth plans. Sciety, Capitainer’s long-term partner, played a key role in connecting the company to the new investor and participated in the funding round. Stockholm-based Capitainer, founded in 2013, has developed Capitainer qDBS, a disposable dried blood spot sampling chip that measures and stores an exact blood volume to enable quantitative measurements. The kit is designed for at-home use by non-healthcare professionals, eliminating common human error in sampling and allowing patients to mail samples to laboratories without refrigeration or specialised packaging. Capitainer positions the product for patients who need continuous monitoring and expects the solution to save travel and healthcare resources while improving patient experience and healthcare efficiency. The company highlights potential environmental benefits from reduced logistics requirements. To commercialise qDBS, Capitainer announced it closed a share issue of €1.39 million. Investors and company leadership describe the device as able to expand the existing dried blood spot market and to enter a larger clinical home sampling market.

Total raised

$4M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2024